Genomic Health Hopes Decision-Making Study Results Will Drive Colon Cancer Dx Adoption, Payment | GenomeWeb

Originally published Jan. 24. This article has been updated to include comments from Crescendo Bioscience's Ted Snelgrove, who spoke at a personalized medicine conference this week in Mt. View, Calif.

When oncologists use Genomic Health's Oncotype DX colon cancer recurrence test, they change their treatment recommendations in 29 percent of cases, according to the results of a clinical decision-making study.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.

A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.

Researchers report in Nature this week that farming led to genomic adaptations in humans.

The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.